{"product_id":"human-e7-peptide-ymldlqpet","title":"Human E7 Peptide (YMLDLQPET)","description":"\u003cdiv style=\"max-width:1400px; margin:0 auto; padding:40px 20px; font-family:'Open Sans',sans-serif; font-weight:300; background:#fff; color:#333; font-size:0.95rem; box-sizing:border-box;\"\u003e\n  \u003cdiv style=\"display:flex; flex-direction:column; gap:20px;\"\u003e\n\u003ch2 style=\"margin:0; font-weight:600;\"\u003eHuman E7 Peptide (YMLDLQPET) – Catalog #B2026677\u003c\/h2\u003e\n\u003cp\u003eThe Human E7 Peptide (YMLDLQPET; Catalog #B2026677) is a peptide sequence derived from the E7 protein of human papillomavirus, supplied as 1 mg of lyophilized powder. The HPV E7 protein is a key oncoprotein that contributes to cell proliferation by interfering with the retinoblastoma (Rb) protein and other regulatory proteins. The E7 peptide YMLDLQPET is recognized by CD8+ cytotoxic T lymphocytes in HPV-infected individuals and is used in research on HPV immunity, vaccine design, and diagnostic immunoassays.\u003c\/p\u003e\n\u003cdiv style=\"overflow-x:auto; max-width:100%; margin-bottom:20px;\"\u003e\n\u003ctable style=\"width:100%; max-width:640px; border-collapse:collapse;\"\u003e\n\u003ctbody\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eCatalog number:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eB2026677\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eLot number:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBatch dependent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eExpiration Date:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBatch dependent\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eAmount:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003e1 mg\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eMolecular Weight:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003e1109.26 Da\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003ePeptide sequence:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eYMLDLQPET\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eSupplied as:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eLyophilized powder\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eSource:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eHuman papillomavirus E7 protein\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eApplications:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eT-cell immunology research, vaccine development studies, HPV-specific immune response detection, immunological assays, epitope mapping\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eStorage:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003e–20°C\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eKeywords:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eHuman E7 peptide, E7 epitope, HPV E7, E7 antigen, E7 immunogen, E7 peptide sequence, human papillomavirus E7, HPV oncogene\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr style=\"border-bottom:1px solid #ddd;\"\u003e\n\u003ctd style=\"width:150px; padding:6px 10px 6px 0; vertical-align:top;\"\u003e\u003cstrong\u003eGrade:\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd style=\"padding:6px 0;\"\u003eBiotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity \u0026gt;18 MΩ-cm) and are filtered through 0.22 µm.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003c\/div\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eScientific Overview\u003c\/h3\u003e\n\u003cp\u003eThe Human E7 Peptide is derived from the HPV E7 oncoprotein, a small (~98 amino acid) viral protein that plays a critical role in HPV-mediated cell transformation and oncogenesis. E7 interacts with and destabilizes the retinoblastoma (pRb) tumor suppressor protein, leading to uncontrolled cell cycle progression and proliferation. The peptide YMLDLQPET corresponds to a region of the E7 protein that is recognized by CD8+ cytotoxic T lymphocytes (CTLs), which are crucial for immune surveillance and clearance of HPV-infected cells. In naturally infected or vaccinated individuals, E7-specific CD8+ T-cell responses are thought to be important for controlling HPV infections and preventing cervical cancer development.\u003c\/p\u003e\n\u003cp\u003eKey applications include:\u003c\/p\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003eStudy of E7-specific CD8+ T-cell responses in HPV-positive samples\u003c\/li\u003e\n\u003cli\u003eVaccine design and efficacy testing in HPV immunization research\u003c\/li\u003e\n\u003cli\u003eHLA-peptide binding assays to identify immunodominant epitopes\u003c\/li\u003e\n\u003cli\u003eDevelopment of diagnostic assays to detect E7-specific immunity\u003c\/li\u003e\n\u003cli\u003eComparative immunology studies across HPV types and variants\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eUsage \u0026amp; Handling Guidance\u003c\/h3\u003e\n\u003cp\u003eReconstitute the lyophilized powder in sterile water or appropriate buffer immediately before use. The peptide is stable at the concentrations used in most immunological assays.\u003c\/p\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eReconstitution:\u003c\/strong\u003e Dissolve in sterile water, PBS, or an appropriate culture medium at your desired concentration (typically 0.1–10 µM for immunological applications).\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePurity:\u003c\/strong\u003e The peptide is supplied in lyophilized form with high purity; request the COA for detailed analysis if needed.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eStorage:\u003c\/strong\u003e Keep the lyophilized powder at –20°C. After reconstitution, store solutions at 2–8°C for short-term use or at –20°C for longer storage.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eWhat You Get\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e1 mg of synthesized Human E7 Peptide (YMLDLQPET)\u003c\/li\u003e\n\u003cli\u003eLyophilized powder for convenient storage and reconstitution\u003c\/li\u003e\n\u003cli\u003eHigh-purity peptide suitable for immunological research\u003c\/li\u003e\n\u003cli\u003eFor research use only (RUO)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eWhy Researchers Choose It\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003eSequence derived from a known CD8+ T-cell epitope in HPV E7\u003c\/li\u003e\n\u003cli\u003eUseful for studying immune responses to HPV infection and vaccination\u003c\/li\u003e\n\u003cli\u003eApplicable to both basic immunology and translational vaccine research\u003c\/li\u003e\n\u003cli\u003eDefined chemical composition for reproducible immunoassays\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch3 style=\"margin-top:30px;\"\u003eFrequently Asked Questions (FAQ)\u003c\/h3\u003e\n\u003cul style=\"padding-left:20px;\"\u003e\n\u003cli\u003e\n\u003cstrong\u003eWhat is the E7 protein?\u003c\/strong\u003e\u003cbr\u003eE7 is a small oncoprotein produced by human papillomavirus (HPV) that inactivates the retinoblastoma (Rb) tumor suppressor protein, contributing to uncontrolled cell proliferation and cancer development.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eIs this peptide recognized by T cells?\u003c\/strong\u003e\u003cbr\u003eYes. The sequence YMLDLQPET is recognized by CD8+ cytotoxic T lymphocytes in HPV-infected individuals, making it a useful tool for studying immune responses to E7.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eHow do I use it in an immunoassay?\u003c\/strong\u003e\u003cbr\u003eTypical applications include ELISPOT assays, flow cytometry, and peptide-HLA binding studies. Reconstitute to your working concentration and use in your chosen assay format.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eCan I get a COA?\u003c\/strong\u003e\u003cbr\u003eYes. Request a quote or contact us and we will provide available lot documentation including purity analysis.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cdiv style=\"margin-top:20px; font-weight:bold; color:#c8102e;\"\u003eThis product is for Research Use Only (RUO). It is not intended for diagnostic or therapeutic use in humans or animals.\u003c\/div\u003e\n\u003chr\u003e\n\u003ch4\u003eReferences\u003c\/h4\u003e\n\u003cul style=\"padding-left:0; margin:0; list-style:none;\"\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eKeskin DB, Reinhold B, Lee SY, Zhang G, Lank S, O'Connor DH, Berkowitz RS, Brusic V, Kim SJ, Reinherz EL. Direct identification of an HPV-16 tumor antigen from cervical cancer biopsy specimens. \u003cem\u003eFront Immunol.\u003c\/em\u003e 2011;2:75.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.3389\/fimmu.2011.00075\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eNilges K, Höhn H, Pilch H, Neukirch C, Freitag K, Talbot PJ, Maeurer MJ. Human papillomavirus type 16 E7 peptide-directed CD8+ T cells from patients with cervical cancer are cross-reactive with the coronavirus NS2 protein. \u003cem\u003eJ Virol.\u003c\/em\u003e 2003;77(9):5464-74.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1128\/jvi.77.9.5464-5474.2003\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003cli style=\"display:flex; justify-content:space-between; align-items:flex-start; gap:12px; padding:8px 0; border-bottom:1px solid #eee;\"\u003e\n\u003cspan style=\"flex:1;\"\u003eBalsitis SJ, Sage J, Duensing S, Münger K, Jacks T, Lambert PF. Recapitulation of the effects of the human papillomavirus type 16 E7 oncogene on mouse epithelium by somatic Rb deletion and detection of pRb-independent effects of E7 in vivo. \u003cem\u003eMol Cell Biol.\u003c\/em\u003e 2003;23(24):9094-103.\u003c\/span\u003e\u003ca href=\"https:\/\/doi.org\/10.1128\/MCB.23.24.9094-9103.2003\" target=\"_blank\" rel=\"noopener\" style=\"flex-shrink:0; margin-top:2px;\"\u003e\u003cimg src=\"https:\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/Reference.png?v=1775409336\" alt=\"Reference\" style=\"height:28px; width:auto;\"\u003e\u003c\/a\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n  \u003c\/div\u003e\n\u003c\/div\u003e","brand":"Molecular Depot","offers":[{"title":"Default Title","offer_id":52813633421610,"sku":"BTS-B2026677","price":705.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0896\/1579\/4474\/files\/B2026677.png?v=1790900045","url":"https:\/\/bluetigerscientific.com\/products\/human-e7-peptide-ymldlqpet","provider":"Blue Tiger Scientific","version":"1.0","type":"link"}